Search
News & Events
Aspire Award funds global learning opportunityDr Renee Ng, a microbiologist specialising in bacteriophage therapy – an alternative to antibiotics to fight antimicrobial resistance – will travel to the world’s premier conference on viruses, bringing new ideas, connections and expertise back to Perth.
Research
Global change, climate change, and asthma in children: Direct and indirect effects - A WAO Pediatric Asthma Committee ReportThe twenty-first century has seen a fundamental shift in disease epidemiology with anthropogenic environmental change emerging as the likely dominant factor affecting the distribution and severity of current and future human disease. This is especially true of allergic diseases and asthma with their intimate relationship with the natural environment.
Research
Surveillance of avian influenza through bird guano in remote regions of the global south to uncover transmission dynamicsAvian influenza viruses (AIVs) pose a growing global health threat, particularly in low- and middle-income countries (LMICs), where limited surveillance capacity and under-resourced healthcare systems hinder timely detection and response. Migratory birds play a significant role in the transboundary spread of AIVs, yet data from key regions along migratory flyways remain sparse. To address these surveillance gaps, we conducted a study between December 2021 and February 2023 using fresh bird guano collected across 10 countries in the Global South.
Research
A complete genome of an obligately lytic Pseudomonas aeruginosa bacteriophage, Minga-mokiny 4We report the isolation of a bacteriophage with obligately lytic activity against Pseudomonas aeruginosa from wastewater. The reported phage, Minga-mokiny 4, appears to belong to the Schitoviridae family, is of the Litunavirus genus, and has a 72,362-bp genome. No known genes associated with lysogeny, bacterial resistance, or virulence were predicted.
Research
Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case seriesEnsitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.